A Phase II failure for Californian cell therapy company Atara Biotherapeutics (Nasdaq: ATRA) has prompted a share sell-off, with the company’s stock falling 80% in value on Thursday.
The immunotherapy specialist is using its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop therapies for people with cancer and autoimmune diseases.
Primary analysis data show that the Phase II EMBOLD study of ATA188 did not meet its primary endpoint, with fluid and imaging biomarkers also failing to provide evidence of efficacy.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze